AstraZeneca Pharma India posted a strong Q2 FY26 with a 41% YoY rise in net profit to ₹542.2 million and a 37% jump in revenue to ₹5.59 billion. Key growth drivers included oncology sales, new product launches, and regulatory approvals, reflecting solid operational and strategic performance.
AstraZeneca Pharma India Ltd has reported a robust financial performance for the second quarter of FY26, showcasing strong growth across key metrics. The company’s strategic focus on innovation and operational efficiency has paid off, with significant gains in both revenue and profitability.
Key Highlights from Q2 FY26 Results:
-
Revenue from operations rose 37% YoY to ₹559 crore, driven by strong demand across therapeutic segments.
-
Net profit surged 41.1% YoY to ₹54.2 crore (₹542.2 million), up from ₹38.4 crore in Q2 FY25.
-
EBITDA increased 43.7% YoY to ₹75.4 crore, reflecting improved cost management and operational leverage.
-
Operating margin expanded to 13.5%, up from 12.9% in the previous year’s quarter.
-
The Oncology segment led growth, posting a 48.6% increase in revenue.
-
The company launched Eculizumab, strengthening its product portfolio in rare disease treatment.
-
Seven new regulatory approvals were secured during the quarter, reinforcing AstraZeneca’s commitment to innovation.
-
Despite strong results, shares closed 1.86% lower at ₹9,012 on NSE ahead of the earnings release.
These results underscore AstraZeneca Pharma India’s resilience and strategic execution in a competitive healthcare landscape.
Sources: CNBC TV18, ScanX News